MGA 012

Drug Profile

MGA 012

Alternative Names: MGA012

Latest Information Update: 14 Jan 2017

Price : $50

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 13 Dec 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (unspecified route)
  • 02 Nov 2016 MacroGenics files an IND application with the US FDA before November 2016
  • 02 Nov 2016 The US FDA approves IND application for MGA 012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top